Earnings release
Page 1
August 4 , 2026 DiaMedica THERAPEUTICS DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11 , 2026 MINNEAPOLIS -- ( BUSINESS WIRE ) -- DiaMedica Therapeutics Inc. ( Nasdaq : DMAC ) , a clinical - stage biopharmaceutical company focused on developing novel treatments for preeclampsia , fetal growth restriction and acute ischemic stroke ( AIS ) , today announced that its second quarter 2026 financial results will be released after the markets close on Monday , August 10th DiaMedica will host a live conference call on Tuesday , August 11th at 8:00 AM Eastern Time / 7:00 AM Central Time to provide a business update and discuss financial results . Conference Call details : Date : Time : Web access : Dial In : Conference ID : Tuesday , August 11 , 2026 8:00 AM EDT / 7:00 AM CDT https://app.webinar.net/d01wEPk9peA ( 646 ) 357-8766 2224408 Interested parties may access the conference call by dialing in or listening to the simultaneous webcast . Listeners should log on to the website or dial in 15 minutes prior to the call . The webcast will remain available for play back on the Company's website , under investor relations - events and presentations , following the earnings call and for 12 months thereafter . A telephonic replay of the conference call will be available until August 18 , 2026 , by dialing ( 800 ) 770-2030 ( US Toll Free ) and entering the replay passcode : 2224408 # . About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on preeclampsia , fetal growth restriction and acute ischemic stroke . DiaMedica's lead candidate DM199 is the first pharmaceutically active recombinant ( synthetic ) form of the KLK1 protein , an established therapeutic modality in Asia for the treatment of acute ischemic stroke , preeclampsia and other vascular diseases . For more information visit the Company's website at www.diamedica.com . View source version on businesswire.com : https://www.businesswire.com/news/home/20260804858349/en/ Scott Kellen Chief Financial Officer
Page 2
Phone: (763) 496-5118 skellen@diamedica.com For Investor Inquiries: Mike Moyer Managing Director, LifeSci Advisors, LLC Phone: (617) 308-4306 mmoyer@lifesciadvisors.com Media Contact: Madelin Hawtin LifeSci Communications mhawtin@lifescicomms.com Source: DiaMedica Therapeutics Inc.